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Abstract Drug-induced sleep fragmentation can cause sleep disturbances either
via their intended pharmacological action or as a side effect. Examples of distur-
bances include excessive daytime sleepiness, insomnia and nightmares. Developing
drugs without these side effects requires insight into the mechanisms leading to
sleep disturbance. The characterization of the circadian sleep pattern by EEG fol-
lowing drug exposure has improved our understanding of these mechanisms and
their translatability across species. The EEG shows frequent transitions between
speciﬁc sleep states leading to multiple correlated sojourns in these states.
We have developed a Markov model to consider the high correlation in the data
and quantitatively compared sleep disturbance in telemetered rats induced by
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DOI 10.1007/s10928-011-9215-3methylphenidate, which is known to disturb sleep, and of a new chemical entity
(NCE). It was assumed that these drugs could either accelerate or decelerate the
transitions between the sleep states. The difference in sleep disturbance of meth-
ylphenidate and the NCE were quantitated and different mechanisms of action on
rebound sleep were identiﬁed. The estimated effect showed that both compounds
induce sleep fragmentation with methylphenidate being ﬁvefold more potent
compared to the NCE.
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Introduction
Sleep is a highly regulated and dynamic physiologic process. Simplistically, the
regulation of sleep-wakefulness involves reciprocal interactions between two
opposing control systems: one that promotes wakefulness and one that promotes
sleep [1]. Normal vigilance is generally separated into three speciﬁc states: awake
(WAKE), non-rapid eye movement (NREM) and rapid eye movement (REM) sleep
[2]. Most mammals cycle or transition between the different vigilance states at
regular intervals throughout their resting phase and have been shown to respond to
drug in similar way (see Ivarsson et al. [3] for a review). It has been shown
repeatedly that sleep fragmentation (i.e. increased number of transitions between
sleep and wake states) in subjects suffering from sleep disorders or as a direct cause
of pharmaceutically active drugs, is strongly linked to increased daytime sleepiness
[4]. Therefore, the characterization of the time course of the transitions between
different vigilance states could be useful not only to identify mechanisms of action
and screen novel compounds for possible (side) effects, but also to reverse or restore
the physiological processes that are degraded by sleep problems.
The different vigilance states can be identiﬁed using changes in electroenceph-
alography (EEG) and electromyography (EMG) activity: WAKE is characterized by
desynchronized, low amplitude EEG activity and relatively high EMG activity;
NREM displays synchronized, high amplitude EEG activity accompanied by low
EMG activity; whereas REM shows desynchronized low amplitude EEG activity
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123with low or absent EMG activity [5]. Note that the circadian sleep pattern shows
frequent transitions between the vigilance states (these frequencies are higher in rats
compared to human). Besides, the likelihood of next vigilance state is function of
the current vigilance state leading to multiple correlated states. As a result, the
analysis of data from such studies is complex. For instance, proportional odds
models are not suitable since they do not account for the within-individual
dependency in the data while any model aimed at inferring from these data should at
least account for the correlations between the different vigilance states. Markov
models have proved to be suitable for this type of highly correlated longitudinal data
[6]. Hence, most of the recent papers have adopted a Markovian approach to address
this problem [7, 8]. More elaborated models have been developed by Karlsson et al.
[9] and Kjellsson et al. [10, 11] who proposed Markov chain models using a mixed
effects approach by modeling the transition probabilities as binary logistic functions
of nighttime and stage time (duration of last contiguous time spent in a stage). More
recently, Bizzotto et al. [12, 13] has extended this approach by modeling the
transition probabilities using multinomial logistic functions.
The present manuscript differs in several respects from the above papers. Indeed,
all previous works were performed in a clinical drug development setting while in
this paper we describe the development of a continuous time Markov model to
assess sleep fragmentation in a pre-clinical setting. On the other hand, the transition
probabilities of the Markov model were directly derived from the so-called
Kolmogorov (forward–backward) equations that describe their time-evolutions [6].
Moreover, the sleep states were modeled as hidden states of the Markov model. We
applied this approach to compare the effects of methylphenidate, a powerful
stimulant which can signiﬁcantly disturb sleep, and of a new chemical entity (NCE)
that potentially could affect sleep fragmentation. To the best of our knowledge, this
is the ﬁrst manuscript using a hidden Markov model to model sleep fragmentation
and also the ﬁrst to implement such a model in NONMEM.
Materials and methods
Study design
Methylphenidate (Ritalin
) is a psychomotor stimulant that is commonly used in the
treatment of Attention deﬁcit/hyperactivity disorder (ADHD). The NCE is a lead
compound for an internal project that potentially could affect sleep fragmentation.
TheeffectsofmethylphenidateandtheNCEonsleepweredeterminedontwocohorts
ofrats(n = 6–8pergroup)inaplacebocontrolledcross-overdesign.Ratswereorally
dosedwithcompoundorvehicleatlightonsetinaLatinsquaredesignandreceivinga
single dose of 3, 10 or 30 mg of methylphenidate or 2, 6.7, 20, 26.8 or 40 mg of the
NCE. The doses of methylphenidate were based on previously published data
showing effects onsleepand locomotor activity [14,15,16] andthe doses ofthe NCE
were chosen to cover the range from approximately 0.3 to 10 times the 12 h average
freeplasmamultiplesoftheprimarypharmacology(basedoninternalinvitroassays).
Recording of EEG and EMG signals began immediately after dosing and continued
J Pharmacokinet Pharmacodyn (2011) 38:697–711 699
123foratleast12 h.Thesleepstageanalysiswasperformedwithanautomaticsleepstage
discriminator based on similar logic described previously [5] to allocate every 12 s
epoch to one of the three vigilance states, WAKE, NREM (non-REM) and REM. The
scores were subsequently aggregated in 5 min epoch and the residence times in each
of the three vigilance states were reported.
Animals
Male Sprague–Dawley rats (Charles River, Margate, UK, approximately 300 g at
time of surgery) were singly housed under a 12 h light/dark cycle (lights on at 11:00
am) with food and water ad libitum. As described previously [5, 17], animals were
implanted with radiotelemetric transmitters (Data Sciences International, St. Paul,
MN, USA) intraperitoneally under isoﬂurane anaesthesia for the recording of the
EEG and EMG and were allowed to recover from the implantation of the device for
at least 2 weeks, and the experiment was started once the animals were certiﬁed ﬁt
to continue by a veterinary surgeon. All experiments were performed in accordance
with the ethical guidelines for animal research and fully complied with Home Ofﬁce
legislation.
Hidden Markov model
In this analysis only two vigilances states were considered: the WAKE and the
SLEEP state, with the latter obtained by merging the vigilance sleep stages REM and
NREM sleep. In every 5 min epoch, the time spent in each of the vigilance states
(residence time) was reported. A model that aims at inferring from these data should
not discard the dependency between these observations. While the analysis of such
dense and continuous data (in the rest of this paper by continuous data, we mean the
length of sojourn in a vigilance state), when taking into account the dependency
between observations, is theoretically feasible (using for example autoregressive
models such as in time series analysis) it can be computationally prohibitive.
Therefore, we decided to binarize the data (the length of sojourn is binarized) by
deﬁning a cut-off point. The cut-off point was arbitrary chosen to be 2.5 min. When
the residence time in the WAKE state was less or equal to 2.5 min, the animal was
assumed to be in the SLEEP state and the observation was reset to 0. On the other
hand when the residence time in the WAKE state was greater than 2.5 min, the
animal was assumed to be in the WAKE state and the observation was reset to 1.
Under the additional assumption that at any given time the next vigilance state is fully
and only dependent on the present vigilance state, sleep fragmentation would possess
the Markov property (the Markov property is characterized by two main assump-
tions: the present depends on the past and given the present, the future is independent
from the past). Thus a Markov model could be used to model such data.
However, due to the arbitrarily selected cut-off point, the binarization could be
biased leading to misclassiﬁcation of the observations. Determining the cut-off with
the least misclassiﬁcation errors could be a way to overcome this problem but our
attempts to estimate this point were unsuccessful. Instead, we used a hidden Markov
model to account for misclassiﬁcation errors.
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123A hidden Markov model is a Markov model whose states are not observed
(hidden). In a regular Markov model, there is a one-to-one relationship between the
observations and the states. In our setting, for instance, the state SLEEP corresponds
to observing 0. In a hidden Markov process, the states are not anymore identiﬁable
from the observations. Hence, the observation might be set to 0, whereas the animal
is actually awake. Therefore the sleep status was modelled as a continuous time
two-state hidden Markov model (Fig. 1) which accounts for the misclassiﬁcations
induced by the binarization.
All inferences are conditional on the observation times. Let P01 and P10 (Fig. 1)
denote respectively the transition probabilities from the SLEEP state to the WAKE
state and vice versa. P00 and P11 (Fig. 1) are the probabilities of not moving from the
present state; SLEEP and WAKE respectively. Identiﬁcation of the hidden Markov
model requires the present state, P01 and P10 and also the probability of
misclassiﬁcation to be known. The probability of observing 1 when the true state is
SLEEP (i.e. misclassifyinga0asa1)andtheprobabilityofobserving1whenthe true
stateisWAKE(i.e.correctclassiﬁcationintheWAKEstate)aredenotedbyP0andP1
respectively. Ideally, the probability of misclassiﬁcation should be low, resulting in a
P0 close to 0 and P1 close to 1. Hence P0 is conceptually analog to a type I error,
whereasP1tothepowerofwrongclassiﬁcationoftheobservations.Thisalsoprovides
an indication on whether the arbitrary selected cut-off point was appropriate or not.
A Markov model can, by deﬁnition, be parameterized by its intensities of
transition. This can be achieved by solving the system of Kolmogorov’s differential
equations [6]. Let u and v denote the intensities of transitioning from WAKE to
SLEEP and from SLEEP to WAKE respectively. For a two-state Markov process,
the transition probabilities over a time interval t are shown in Eqs. 1 and 2 for P01
and P10 respectively, in which u is the intensity of acquisition of sleep while v is the
intensity of clearance of sleep.
P01 t ðÞ¼
v
u þ v
1   e  uþv ðÞ t

ð1Þ
P10 t ðÞ¼
u
u þ v
1   e  uþv ðÞ t

ð2Þ
As mentioned above t is the length of a time interval. Since each individual is
observed at successive time points, the contribution of each subject to the likelihood
is function of these transitions probabilities where t is the time between two
consecutive observations.
Fig. 1 Two-state hidden Markov process
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The pharmacokinetics of methylphenidate and the NCE were described with
compartmental models with ﬁrst order absorption and elimination. The PK
parameters were estimated on internal Pﬁzer data from satellite PK experiments
in rats, using a population PK modelling approach (data not shown). The estimated
PK parameters for a typical rat were subsequently used to simulate the PK in the
PK-PD model. The typical estimated values for the maximum plasma concentration
and the time at which the peak concentration is reach are provided in Table 1 for
both compounds.
Placebo and drug effect models
The intensities are the rates of transitioning from one state to another. These rates
are the inverse of the residence times, which are known to be exponentially
distributed [6]. It was assumed that drugs can change these intensities. Several
models (linear, power and Emax) for the effects of drugs on these intensities were
explored. For sake of conciseness, only the results of the Emax model are reported
in this manuscript as that was the best model according to the Bayesian Information
Criterion (BIC). However the classical Emax model provided non-signiﬁcant
estimates of the EC50. Hence we decided to use the (generally) more ﬂexible
model, a version of the 4-parameter logistic model [18] to estimate the effect of the
drug on both intensities (note that the 4-parameter logistic model is a speciﬁc
parameterization of the sigmoidal model in which a baseline and a slope factor can
also be speciﬁed: here these two parameters are ﬁxed to zero and one respectively
and only the remaining two parameters are estimated). The possible delay in the
onset of the drug effect relatively to drug exposure was tested on both intensities via
an effect-compartment. However, in the ﬁnal model (selection based on the BIC and
the parameter precisions); this delay was included for the acquisition of sleep only.
In this placebo controlled experiment, it was assumed that the placebo treatment
could also change the transition intensities.
More speciﬁcally, the intensities u and v are given by Eqs. 3 and 4, in which u0
and v0 are the baseline intensities, Pmax the maximum placebo effect, which will
wash-out with an equilibrium half-life Teq,plac. The latter was assumed to be the
Table 1 PK parameter estimates
Parameter Compound 2 mg 6.7 mg 20 mg 26.8 mg 40 mg 3 mg 10 mg 30 mg
Tmax (min) NCE 1.05 1.1 1.2 1.25 1.3
Methyl-
phenidate
0.2 0.2 0.2
Cmax (nM) NCE 21 71 232 323 516
Methyl-
phenidate
44 146 438
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123same for both intensities. The drug effects on the intensities u and v (Drgu and Drgv)
are described by Eqs. 5 and 6 respectively, in which Cp is the drug concentration in
plasma and Ce is the concentration in the hypothetical effect compartment, which is
derived from Eq. 7 describing the delay or hysteresis between the plasma and effect
concentration using the equilibrium constant ke0 and an equilibrium half-life Teq,drug
of ln(2)/ke0. Emax is the maximum drug effect while EC50 is the plasma or effect
compartment concentration corresponding to half of the maximum drug effect.
u ¼ exp u0 þ Pmaxue ðlnð2Þ=Teq;placÞt þ Drgu

ð3Þ
v ¼ exp v0 þ Pmaxve ðlnð2Þ=Teq;placÞt þ Drgv

ð4Þ
Drgu ¼ Emaxu  
Emaxu
1 þ Ce
EC50u exp Ce   EC50u ðÞ
ð5Þ
Drgv ¼ Emaxv  
Emaxv
1 þ
Cp
EC50v exp Cp   EC50v
 ð6Þ
dCe
dt
¼ ke0 Cp   Ce

ð7Þ
Note that in Eqs. 3 and 4, the time t is TAD.
It was assumed that the misclassiﬁcation errors were highest around the cut-off
point and decrease exponentially as a function proportional to the distance from that
point (2.5 min). More speciﬁcally:
P0 ¼
1
1 þ exp  d:h0 ðÞ
ð8Þ
P1 ¼
1
1 þ exp  d:h1 ðÞ
ð9Þ
d ¼ exp   l   2:5 jj ðÞ l is length of time in WAKE ð10Þ
The parameters h0 and h1 are to be estimated.
We set an additional constraint on both P0 and P1;i fl is greater than 4 P0 is set to
0 and when l is less than 1 P1 is set to 0. The meaning of this latter constraint is that
the probability of misclassiﬁcation is zero when and only when the length of
consecutive time in WAKE is less than 1 min or greater than 4 min during the
5 min epoch.
Software and model evaluation
The model parameters were estimated by maximizing the likelihood of the model
using the Laplacian method in the nonlinear mixed effect modelling package
NONMEM (version 7.1.2; Icon Development Solutions, Ellicott City, Maryland,
USA). At each time point the residual on frequency of the WAKE state (including
all subjects and all scenarios) divided by their variances were calculated to
provide for both compounds the time course of the weighted residuals in Fig. 3.
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S-Plus
 for Windows (version 8.0 Professional, release 1, Insightful Corp.,
Seattle, USA). This was achieved by simulating 100 replicate datasets using the
ﬁnal model (parameters and uncertainty). The hidden Markov property of the
model was then applied to each sample of parameters. This means that for a given
observation and a given sleep state at the present time, the next sleep status was
predicted by sampling from a Bernoulli distribution with the appropriate transition
probability. In this approach, all rats were assumed to be awake at the start of the
experiment. Subsequently, the observation corresponding to that time point was
predicted by sampling from a Bernoulli distribution with the appropriate
misclassiﬁcation probability. These simulations were used to reconstruct for each
dose, the observed frequency over time of animals in the WAKE state (Fig. 4).
For both compounds, the predicted transition probability from awake to sleep over
time for a typical rat is depicted in Fig. 5. To evaluate the overall effect of
methylphenidate and the NCE respectively on sleep fragmentation, the difference
between log ratio of the intensity of acquisition of sleep over clearance of sleep
under active treatment and the same quantity when only placebo is given was
calculated. When this difference is zero the drug has no effect on sleep. A positive
difference shows induction of sleep, whereas wakefulness is promoted when the
difference is negative (Fig. 6). Further evaluations of the model were performed
using the theory of receiver operating characteristic (ROC) curves [19]. Basically,
the predictions are compared to the observations for each individual at each time
point. The ratio of true 1’s (true positive TP: correctly predicted 1 divided by the
total number of 1’s observed) as well as the ratio of false 1’s (false positive FP:
number of observed 0 predicted as 1 divided by the total number of 0’s observed)
are calculated for each time point. However, as the model is a probabilistic model,
we actually need to sample such a contingency table to proceed. This was done as
follows: a threshold is set between 0 and 1. At each time point, for each
individual, the predicted probability of the observation being 1 is compared to the
threshold. When the probability is greater than the threshold then the predicted
observation is set to 1 whereas if it is less than the threshold the prediction is set
to 0. The process is repeated for each threshold (note that this threshold has no
relationship with the cut-off point which was used for the binarization) of the 100
equally spaced points of [0, 1]. The ROC curve is hence obtained (Fig. 7) and its
AUC is an indicator of the predictive performance of the model. We want this
AUC as close as possible to 1. It is generally accepted that an AUC over 0.8
corresponds to a good predictive model.
Results
The observed time course of transitions between SLEEP and WAKE for the two
cohorts of rats receiving methylphenidate and the NCE is shown in Fig. 2. Both
compounds show different changes in the sleep pattern compared to placebo, since
methylphenidate increases the residence time, whereas the NCE increases the
frequency of the transitions.
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123All model parameters (Table 2) could be estimated precisely, since their relative
standard errors were below 50% of the parameter estimates except the Emax for the
effect of methylphenidate on the transition from WAKE to SLEEP, which appears
not to be different from 0. The expected indicator of type I error was less than 0.05
while the expected indicator of power was greater than 0.92. This suggests that the
binarization method was appropriate since it has induced only a low probability of
misclassiﬁcation.
The weighted residuals in Fig. 3 are approximately normally distributed and
were generally within the 95% conﬁdence interval of the standard normal
distribution. This suggests that the model was not misspeciﬁed. The observed and
simulated number of animals in the WAKE state (Panel A vs. panel C and B vs.
panel D in Fig. 4 for methylphenidate and the NCE respectively) closely
resemble, indicating an adequate description of the sleep fragmentation by the
two-state continuous hidden Markov model. Figure 5 shows different patterns for
the transition probability of the NCE compared to methylphenidate. Both
compounds tend to promote wakefulness when compare to placebo, as shown
in Figs. 4 and 6.
Fig. 2 Time course of transitions from WAKE to SLEEP and vice versa for a placebo and
b methylphenidate in the methylphenidate cohort and c the placebo versus d NCE in the NCE cohort. At
the start of the experiment all rats are in the WAKE state. A value of 0 (horizontal line) means no
transition, whereas a positive values indicates a change from WAKE to SLEEP while the reverse is
indicated by a negative value
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123Discussion
For both compounds, the estimated Emax value was higher for the intensity v than for
u (Table 2), suggesting a higher drug effect on the clearance of sleep compared to
the acquisition of sleep. Methylphenidate appears to inhibit the transitions from one
sleep status to another as shown by the negative Emax values, whereas the NCE
stimulates these transitions. As can be observed in Fig. 2b, inhibition of both
transitions by methylphenidate results in longer residence times. In contrast,
stimulating the intensities of the transitions by the NCE increases the number of
transitions between SLEEP and WAKE (Fig. 2d).
Figure 4a, c for methylphenidate and the NCE respectively show that the onset of
acquisition of sleep (i.e. transition from WAKE to SLEEP) is delayed whether the
animal received a placebo or an active treatment. Figure 5a shows that methylphe-
nidate delays the onset of sleep for low doses. There seems to be a dose dependence
decreasing this delay with increasing dose so that the placebo onset of sleep is
almost identical to the high dose onset. Figure 5b shows comparable onsets of sleep
for the placebo and the active doses. The NCE acts as a stimulator of both
intensities, which results in higher transition probabilities with respect to placebo.
This pattern is clearly different from the effects of methylphenidate showing that the
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Fig. 3 Weighted residuals on frequency of the WAKE state for the ﬁt of the hidden Markov model to the
data of a the methylphenidate cohort and b the NCE cohort
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123NCE and methylphenidate have clearly different mechanism of action on sleep
fragmentation.
Figure 6 shows the overall effect of methylphenidate and the NCE respectively
on sleep fragmentation. These were negative for both compounds; suggesting that
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123both methylphenidate and the NCE tend to promote wakefulness when adminis-
trated to rats. However, the maximum effect of methylphenidate was -2.6 while
that of the NCE was ﬁvefold less (-0.55). This suggests that methylphenidate was
much more potent than the NCE in inducing sleep fragmentation in rats.
The predictive performance of the model was evaluated using the ROC curves in
Fig. 7. This shows a higher predictive performance for methylphenidate than for the
NCE though the model performs well for both compounds since the AUC of these
curves were estimated to be 0.86 and 0.93 for the NCE and methylphenidate
respectively.
It has been shown repeatedly that fragmented sleep is less restorative than
consolidated sleep and causes reduced daytime functioning [4]. However, it is still
unclear how to best quantify the fragmentation of sleep and also which speciﬁc
changes in the sleep pattern are directly linked to impairments in daytime
function. Currently, there are unconvincing correlations between sleepiness and
the standard measures of arousals. Therefore, there is a clear need to identify more
sensitive approaches to measure sleep fragmentation and the approach described
here could address some of these questions, but more work and analysis is needed,
especially on clinical data, before any clear conclusions on the applicability can
be drawn.
In conclusion, this manuscript describes the development of a hidden Markov
model to assess drug-induced sleep disturbance across multiple drug classes on the
basis of EEG recordings in rats. Markov models can accommodate highly correlated
observations. Unlike previous papers in this ﬁeld [9–13], the transition probabilities
were derived from the Kolmogorov (forward–backward) equations. This method-
ology can be used to explicitly model the ultradian regulation (REM vs. non-REM).
Here, the REM and NREM were merged into one vigilance stage. Our methodology
is applicable when all three vigilance states are considered as long as the
observations are discrete (using for instance the 12 s epoch instead of the
aggregated data in 5 min). However there may be computational issues with
NONMEM because of the size of the data and the rapidly increasing number of
parameters to estimate. Models such as those developed in [9–13] might then be
more suitable. By binarizing the original observations, the approach adopted in this
paper provides a far less computationally prohibitive method than a method based
on autoregressive models for instance. It should be acknowledged, however, that
binarization of data does, in principle, induce misclassiﬁcation errors. However, the
developed hidden Markov model offers an elegant way of accounting for these
errors which were shown to be acceptable in this analysis. Indeed, it was shown that
the complex sleep pattern in rats was well described by a two-state continuous time
hidden Markov model, which was successfully applied to studies designed to assess
and compare the effects of methylphenidate and an NCE on sleep disturbance in
telemetered rats. This model can be used to quantify differences in sleep
fragmentation and provides insight into the nature of the underlying mechanism
of action of drug inducing sleep fragmentation. As a result, this approach can be
applied to screen NCEs early in development for their possible effects on sleep
fragmentation compared to an active control, such as methylphenidate. For the NCE
evaluated in this paper it was found that it induces sleep fragmentation in a dose-
710 J Pharmacokinet Pharmacodyn (2011) 38:697–711
123dependent manner, but to a much less extent (i.e. ﬁve times less potent) and with a
different mechanism of action compared to methylphenidate.
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